Role of amifostine as a cytoprotectant in children >= 3 years with average risk (AR) medulloblastoma (MB) treated with craniospinal irradiation (CSI) and 4 courses of cisplatin (CDDP)-based high dose chemotherapy.
Publication
, Conference
Fouladi, M; Chintagumpala, M; Ashley, D; Kellie, S; Broniscer, A; Merchant, TE; Kun, LE; Stewart, C; Wallace, D; Gajjar, A
Published in: JOURNAL OF CLINICAL ONCOLOGY
June 20, 2006
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
ISSN
0732-183X
Publication Date
June 20, 2006
Volume
24
Issue
18
Start / End Page
517S / 517S
Location
Atlanta, GA
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
42nd Annual Meeting of the American-Society-of-Clinical-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Fouladi, M., Chintagumpala, M., Ashley, D., Kellie, S., Broniscer, A., Merchant, T. E., … Gajjar, A. (2006). Role of amifostine as a cytoprotectant in children >= 3 years with average risk (AR) medulloblastoma (MB) treated with craniospinal irradiation (CSI) and 4 courses of cisplatin (CDDP)-based high dose chemotherapy. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 24, pp. 517S-517S). Atlanta, GA: AMER SOC CLINICAL ONCOLOGY.
Fouladi, M., M. Chintagumpala, D. Ashley, S. Kellie, A. Broniscer, T. E. Merchant, L. E. Kun, C. Stewart, D. Wallace, and A. Gajjar. “Role of amifostine as a cytoprotectant in children >= 3 years with average risk (AR) medulloblastoma (MB) treated with craniospinal irradiation (CSI) and 4 courses of cisplatin (CDDP)-based high dose chemotherapy.” In JOURNAL OF CLINICAL ONCOLOGY, 24:517S-517S. AMER SOC CLINICAL ONCOLOGY, 2006.
Fouladi M, Chintagumpala M, Ashley D, Kellie S, Broniscer A, Merchant TE, et al. Role of amifostine as a cytoprotectant in children >= 3 years with average risk (AR) medulloblastoma (MB) treated with craniospinal irradiation (CSI) and 4 courses of cisplatin (CDDP)-based high dose chemotherapy. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2006. p. 517S-517S.
Fouladi, M., et al. “Role of amifostine as a cytoprotectant in children >= 3 years with average risk (AR) medulloblastoma (MB) treated with craniospinal irradiation (CSI) and 4 courses of cisplatin (CDDP)-based high dose chemotherapy.” JOURNAL OF CLINICAL ONCOLOGY, vol. 24, no. 18, AMER SOC CLINICAL ONCOLOGY, 2006, pp. 517S-517S.
Fouladi M, Chintagumpala M, Ashley D, Kellie S, Broniscer A, Merchant TE, Kun LE, Stewart C, Wallace D, Gajjar A. Role of amifostine as a cytoprotectant in children >= 3 years with average risk (AR) medulloblastoma (MB) treated with craniospinal irradiation (CSI) and 4 courses of cisplatin (CDDP)-based high dose chemotherapy. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2006. p. 517S-517S.
Published In
JOURNAL OF CLINICAL ONCOLOGY
ISSN
0732-183X
Publication Date
June 20, 2006
Volume
24
Issue
18
Start / End Page
517S / 517S
Location
Atlanta, GA
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
42nd Annual Meeting of the American-Society-of-Clinical-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences